`
`
`
`
`
`
`Paper No. ___
`Filed: February 5, 2018
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_____________________________
`
`
`APOTEX INC., APOTEX CORP., ARGENTUM PHARMACEUTICALS LLC,
`ACTAVIS ELIZABETH LLC, TEVA PHARMACEUTICALS USA, INC., SUN
`PHARMACEUTICAL INDUSTIRES, LTD., SUN PHARMACEUTICAL
`INDUSTRIES, INC., AND SUN PHARMA GLOBAL FZE,
`Petitioners,
`
`v.
`
`NOVARTIS A.G.,
`Patent Owner.
`
`_____________________________
`
`IPR2017-008541
`Patent No. 9,187,405
`
`_____________________________
`
`
`PETITIONERS’ NOTICE OF OBJECTIONS TO EVIDENCE
`
`
`1 Cases IPR2017-01550, IPR2017-01946, and IPR2017-01929 have been joined
`with this proceeding.
`
`
`
`
`
`
`
`
`Case IPR2017-00854
`Patent 9,187,405
`
`TABLE OF CONTENTS
`
`I.
`
`INTRODUCTION ........................................................................................... 1
`
`II.
`
`OBJECTIONS ................................................................................................. 1
`
`1.
`
`Objections to EX2088, and any Reference to/Reliance
`Thereon ....................................................................................... 1
`
`III. CONCLUSION ................................................................................................ 2
`
`
`
`
`-i-
`
`
`
`
`Case IPR2017-00854
`Patent 9,187,405
`
`I.
`
`INTRODUCTION
`
`Pursuant to 37 C.F.R. § 42.64(b)(1), Apotex Inc. and Apotex Corp.
`
`(“Petitioner”) submits the following objections to Novartis A.G. (“Patent
`
`Owner”)’s Exhibit 2088, as listed on Patent Owner’s Exhibit List filed on January
`
`29, 2018, and any reference to or reliance on the foregoing. As required by 37
`
`C.F.R. § 42.62, Petitioner’s objections below apply the Federal Rules of Evidence
`
`(“F.R.E.”).
`
`II. OBJECTIONS
`1. Objections to EX2088, and any Reference to/Reliance Thereon
`
`Grounds for Objection: F.R.E. 401, 402 (Irrelevant Evidence Inadmissible);
`
`F.R.E. 403 (Excluding Evidence for Prejudice, Confusion, Waste of Time, or Other
`
`Reasons); F.R.E. 602 (Foundation); F.R.E. 701, 702, 703 (Expert Foundation and
`
`Opinions); F.R.E. 802-805 (Inadmissible Hearsay).
`
`Petitioner objects to EX2088 as irrelevant, confusing, or a waste of time as
`
`Mr. Waibel does not purport to have any percipient knowledge regarding the
`
`substantive facts at issue in the case and EX2088 is not cited in Patent Owner’s
`
`Response. F.R.E. 401, 402, 403. Petitioner objects to EX2088 as failing to
`
`establish that Mr. Waibel has personal knowledge of the matters addressed in his
`
`declaration. F.R.E. 602. Mr. Waibel fails to establish that EX2088 is appropriate
`
`lay or expert opinion testimony under any of F.R.E. 701-703. Moreover, Mr.
`
`
`-1-
`
`
`
`Case IPR2017-00854
`Patent 9,187,405
`
`Waibel’s declaration contains and relies upon hearsay and hearsay within hearsay
`
`for which no applicable exception applies. F.R.E. 802-805.
`
`III. CONCLUSION
`
`Exhibit 2088 was served together with Patent Owner’s Opposition to
`
`Additional Discovery filed on January 29, 2018. These objections are made within
`
`5 business days of filing pursuant to 37 C.F.R. § 42.64.
`
`Respectfully submitted,
`
`/ Steven W. Parmelee /
` Steven W. Parmelee, Lead Counsel
` Reg. No. 31,990
`
`
`
`
`
`
`Dated: February 5, 2018
`
`
`
`
`
`
`
`
`
`
`
`
`
`-2-
`
`
`
`Case IPR2017-00854
`Patent 9,187,405
`
`CERTIFICATE OF SERVICE
`
`
`
`This is to certify that I caused to be served a true and correct copy of the
`
`foregoing Petitioners Apotex Inc. and Apotex Corp.’s Notice of Objections to
`
`Evidence, on this 5th day of February, 2018, on the Patent Owner at the
`
`correspondence address of the Patent Owner as follows:
`
`Jane M. Love, Ph.D.
`Robert W. Trenchard
`GIBSON, DUNN & CRUTCHER LLP
`200 Park Avenue, 47th Floor
`New York, NY 10166
`Email: jlove@gibsondunn.com
`Email: rtrenchard@gibsondunn.com
`
`
`
`
`
`
`
`
`Dated: February 5, 2018
`
`
`
`
`
`
`Respectfully submitted,
`
`/ Steven W. Parmelee /
` Steven W. Parmelee, Lead Counsel
` Reg. No. 31,990
`
`
`
`
`
`-3-
`
`